Volition Develops a New Improved Nu.Q™ Assay Format
AUSTIN, Texas, Jan. 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its Nu.Q™ assays leading to a step-change improvement in...
VolitionRx Completes Acquisition of Octamer GmbH
AUSTIN, Texas, Jan. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for approximately$725,000, consisting of cash and sh...
VolitionRx Limited Announces Strategic Acquisition
AUSTIN, Texas, Dec. 16, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately$725,000 consisting of cash and shares of r...
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
AUSTIN, Texas, Dec. 5, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded$820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB) was awarded$230,000 (€206,000 Euros) each in the form ...
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
AUSTIN, Texas, Dec. 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("N...
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, Nov 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter endedSeptember 30, 2019. Volition management will host a conference call tomorrow,November 13, at 8:30 a.m. U.S. Eastern ...
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced it will host a conference call onWednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providin...
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further$500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its sub...
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding withTexas A&M University ("Texas A&M"), a memb...
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...
Volition Appoints Dr. Phillip Barnes to Board of Directors
AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr.Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effectiveOctober 9, 2019. Dr. Barnes was also appointed to the Company's Audit, C...
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could ...
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase$4.8 million in aggregate amount of shares of our common stock...
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platf...
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately$1.4 million from the Walloon Region, Belgium. To date, Agen...
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2019. Volition management will host a conference call tomorrow,May 9, at 8:30 a.m. U.S. Eastern Time to dis...
VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer
AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale ...
VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onThursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update. ...
